Kalaris Therapeutics Inc (KLRS) has a negative trailing P/E of -3.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -31.40%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -10.6 | 0.00 | 1.20 | 22.75 | - |
| 2019 | -1.1 | -0.01 | 0.21 | 156.46 | - |
| 2020 | -0.2 | 0.00 | 0.03 | 0.00 | - |
| 2021 | -0.1 | -0.03 | 0.11 | 0.00 | - |
| 2022 | -2.0 | 0.10 | -1.00 | 0.00 | - |
| 2023 | -2.8 | 0.17 | -0.92 | 0.00 | - |
| 2024 | -0.8 | 0.01 | 0.40 | 0.00 | - |
| 2025 | -3.0 | 0.04 | 1.63 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2022 | $0.00 | $0.00 | $-15.49M | - |
| 2023 | $0.00 | $0.00 | $-14.7M | - |
| 2024 | $-11.73 | $0.00 | $-58.77M | - |
| 2025 | $-2.85 | $0.00 | $-43.44M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.26 | $-2.60 – $-1.78 | $0.00 | $0.00 – $0.00 | 5 |
| 2027 | $-1.45 | $-2.25 – $0.77 | $13.33M | $13.33M – $13.33M | 5 |
| 2028 | $-1.97 | $-2.40 – $-1.36 | $0.00 | $0.00 – $0.00 | 4 |
| 2029 | $-1.88 | $-1.88 – $-1.88 | $6.53M | $6.53M – $6.53M | 2 |
| 2030 | $-1.76 | $-1.76 – $-1.76 | $21.89M | $21.89M – $21.89M | 2 |
